Potential Efficacy News Today

The following is a summary of "Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN" published in the December 2022 issue of Gastroenterology by Yerushalmy-Feler et al. Although there were no data for children, increasing the maintenance

/PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one...

FinancialNewsMedia.com News Commentary PALM BEACH, Fla, Nov. 15, 2022 /PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs.

Clinical Trial UpdateDAVIE, FL / ACCESSWIRE / November 15, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative

MIAMI, FL / ACCESSWIRE / February 8, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced

Organicell And Proxima CRO Set To Open Clinical Trial For Long Hauler COVID-19 Patients PRESS RELEASE Miami, FL Miami -Organicell Regenerative Medicine, Inc. , a... | February 8, 2022

MIAMI, FL / ACCESSWIRE / December 29, 2021 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, is pleased

Some nutritional supplements may help prevent or mitigate COVID-19 severity With hundreds of thousands of new cases being reported every day, over a year after its onset, the coronavirus disease 2019 (COVID-19) pandemic is still making its presence felt worldwide. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pandemic is estimated to be about ten-fold bigger than the number of reported infections. It has proved difficult to contain the spread of SARS-CoV-2 beca...

(1) DUBLIN, Jan. 14, 2021 /PRNewswire/ -- Results from a National Institute on Drug Abuse (NIDA)-funded study evaluating the efficacy and safety of naltrexone for extended-release injectable suspension (XR-NTX) administered once every three weeks plus oral extended-release bupropion administered daily as a combination treatment for adults with moderate or severe methamphetamine use disorder (MUD) were published today by Dr. Madhukar H. Trivedi et al. in the New England Journal of Medicine (NEJ...